RE:RE:RE:Unreal 1.) Sales continue to improve. Sales are rising, not falling as some who read your post might falsely believe. Moreover, analyst expectations are now more in line with the reality of actual sales so the chances of seeing analyst reports bemoaning "disappointing sales" is probably over. We may even see those reports celebrating better than expected sales now that expectations are more in line with reality.
Sales are definetely not as great as what they said/expected!!
2.) There has been plenty of insider buying in the last 12 months and not much on the selling front. Insiders are also not allowed to transact in the stock very often so it is not always the best indicator. But to the extent that they have transacted in recent months, it has been on the buy side.
Insiders owning is very minuscul for such a "promising" company!!
3.) That is real money in the bank. I have never known a bank to take fake money! I suppose you are alluding to the covertible offsetting the real money inthe bank but the convertible does not come due until 2023 and there is a very good chance it wil convert before it comes due. If so, there will be no need to pay it back. If you think the chances of it converting are low, you are probably so worn out by the last year's stock performacne that you can't think straight about what the future could be.
Not real money, man has to hope (again) that the share price will be much higher in 2023, otherwise.........
4.) They have filed for NASDAQ listing, so it is about as certain as it can get before it actually happens, probably in the next few weeks or so.
"Once upon a time"..........., they were allready on the Nasdaq years ago, didn't do them good! (do you think analists/funds/US investors will be happy with their communicating about sales numbers????
5.) I don't recall the company making many promises so I am not sure what you are talking about there. Luc did say that June Trogarzo sales at least matched Egrifta sales so that piece of guidance has apparently been met. Not sure what other promises were made - maybe you can remind me.
They would become the greatest pharma in Canada, they would surpass 2 B CAD!!!! and both sales numbers of E and T would have been much better now.......
6.) BOD's are normally silent and let the CEO do the tlaking. There is nothing unusual about that at all.
That is a great problem, cause the don't communicate in a norml proper way acompany ought to do!!! There is no respect for us shareholders!
7.) Not sure what you are referring to regarding the call from the CFO but you might want to give him a call and see if he will tak to you.
He answered a mail i wrote(with my 10 points.....) and said they don't answer questions on paper/mail, so he would call me back...................., never heard of him!!!
Here are some of the things we will see soon.
1.) NASDAQ listing
2.) Grinspoon article published
3.) F4 Egrfita launched
4.) Form 40-F released (part of the requirement for listing on NASDAQ
5.) Some news on the IV Push Trogarzo trial
6.) Q3 financial results
7.) File for HIV NASH phase III and Egrifta label extension sent to the FDA (don't think this will be made public, but not sure)
8.) FDA decision on phase III HIV NASH trial and label extension
9.) THERF decision on whether to pursue general NASH
10.) If there is a positive FDA decision on the phase III, then there will likely be a share offering which will bring the company much more visiability among US investors
I admire your optimistic approach and like i said will hold my renewed investing shares for a few months longer (but am very happy i sold earlier on the gros of my holdings!!!!) .
But only more visibility will NOT work in the US, they have to DELIVER!!!!!!
The key thing for the stock is to get that additional visibility and that seems to only come via a share issue. Companies inthe NASH space that have offered shares recently (AKRO, NGM, GNFT) have market caps of $660 million to $1.2 billion. On the other hand, GALT, another NASH player who recently did a company-backed rights issue versusu selling shares through Wall Street brokers, has a market cap of $187 million despite being further along inthe testing process than any of the three companies that issued shares through brokers.
To get TH's HIV NASH opportunity valued properly, the company needs to do an offering at some point and the most logical point is after the FDA gives its blessing for their phase III plans.
There is a lot ot look forward to so you no longer need to look in te rear view mirror.